

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Figdor et al.

**Serial No.:** To be assigned

**Filed:** March 25, 2004

**For:** MELANOMA ASSOCIATED  
PEPTIDE ANALOGUES AND VACCINES  
AGAINST MELANOMA

**Examiner (presumed):** S. Rawlings, Ph.D.

**Group Art Unit (presumed):** 1642

**Attorney Docket No.:** 2578-4230.1US

**NOTICE OF EXPRESS MAILING**

Express Mail Mailing Label Number: EV326919876US

Date of Deposit with USPS: March 25, 2004

Person making Deposit: Christopher Haughton

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US- 2002/0076392 A1	06-20-2002	Hoo
#US- 4,485,086	11/27/1984	Wong
#US- 5,376,531	12/27/1994	Anderson et al.
#US- 5,783,567	07-21-1998	Hedley et al.
#US- 5,844,075	12-01-1998	Kawakami et al.
#US- 5,874,560	02-23-1999	Kawakami et al.
#US- 5,891,432	04-06-1999	Hoo
#US- 5,965,381	10-12-1999	van der Bruggen et al.
#US- 5,965,535	10-12-1999	Chaux et al.
#US- 5,994,523	11-30-1999	Kawakami et al.
#US- 6,245,525 B1	06-12-2001	Martelange et al.
#US- 6,270,778 B1	08-07-2001	Kawakami et al.
#US- 6,291,430 B1	09-18-2001	Chaux et al.
#US- 6,303,756 B1	10-16-2001	Martelange et al.
#US- 6,369,211 B1	04-09-2002	Chaux et al.
#US- 6,407,063 B1	06-18-2002	Luiten et al.
#US- 6,426,217 B1	07-30-2002	Chaux et al.
#US- 6,500,919 B1	12/31/2002	Adema et al.
#US-4,405,712	09-20-1983	Vande Woude et al.
#US-4,497,796	02-05-1985	Salser et al.
#US-4,727,028	02-23-1988	Santerre et al.
#US-4,740,463	04-26-1988	Weinberg et al.
#US-5,190,931	03-02-1993	Inouye
#US-5,208,149	05-04-1993	Inouye
#US-5,262,177	11-16-1993	Brown et al.
#US-5,342,774	08-30-1994	Boon et al.

**Attorney Docket No.: 2578-4230.1US**

#US-5,518,913	05-21-1996	Massie et al.
#US-5,837,511	11-17-1998	Falck-Pedersen et al.
#US-5,994,106	11-30-1999	Kovesdi et al.
#US-5,994,128	11-30-1999	Fallaux et al.
#US-6,033,908	03-07-2000	Bout et al.
#US-6,040,174	03-21-2000	Imler et al.
#US-6,537,560	03-25-2003	Kawakami et al.
#US-2003/0144482 A1	07-31-2003	Kawakami et al.

**Foreign Patent Documents**

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#WO 00/20445	04-13-2000	Chaux
#WO 00/20581	04-13-2000	Ludwig Institute
#WO 95/29193	11-02-1995	The Government of the United States
#WO 98/31398	07-23-1998	Pangaea Pharmaceuticals, Inc.
#WO 99/06544	02-11-1999	The Immune Response Corp.
#WO 99/14326	03-25-1999	Ludwig Institute
#WO 99/45098	09-10-1999	van der Bruggen
#WO 99/53061	10-21-1999	Ludwig Institute
#EP 0 668 350 A	08-23-1995	Akzo Nobel N.V.
#EP-0174608	03-19-1986	Leavitt
#WO 92/21767	12-10-1992	Bristol-Myers
#WO 93/14189	04-22-1993	Ludwig Institute
#WO 94/23067	10-13-1994	Abbott Labs
#WO 94/28152	12-08-1994	Transgene S.A.
#WO 95/02697	01-26-1995	Rhonepoulenc Rorer S.A.
#WO 95/22561	08-24-1995	Univ. of Virginia
#JP9027482A2	01-28-1997	Speedfam Co.

Other Documents

#ADEMA et al., Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA, The American Journal of Pathology, 1993, Vol. 143, No. 6, pp. 1579-1585.

#ADEMA, et al., Molecular Characterization of the Melanocyte Lineage-specific Antigen gp100, J. Biol. Chem., 1994, Vol. 269, No. 31, pp. 20126-20133

#ARCECI, RJ., The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, 1998, pp. 80-93, Vol. 76.

#BAKKER et al., Int J. Cancer, 1997 Jan 27, pp. 302-9, Vol. 70 (3).

#BODEY et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, 2000, pp. 2665-76, Vol. 20.

#BOON, T., Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, 1992, pp. 177-210, Vol. 58.

#BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Biol., 1990, 11:2129-2138.

#COX et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 1994, pp. 716-19, Vol. 264.

#CURTI, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.

#DE VRIES et al., Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and inhuman melanocytic lesions, Cancer Research, 1997, pp. 3223-3229, Vol. 57, No. 15.

#European Search Report, EP 94 20 0337, dated 27 July 1994.

#EZZELL, C., Cancer "vaccines": an idea whose time has come?, Journal of NIH Research, pp. 46-49, Vol. 7.

#GAO et al., Tumor vaccination that enhances antitumor T-cell responses does not inhibit th growth of established tumor, Journal of Immunotherapy, 2000, pp. 643-53, Vol. 23, No. 6.

#GURA, T., Systems for identifying drugs are often faulty, Science, 1997, pp. 1041-42, Vol. 278.

#HU et al., Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, 1996, pp. 2479-83, Vol. 56.

#JAEGER et al., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, 1996, pp. 162-69, Vol. 66, No. 2.

#KRISTENSEN et al., Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor, Febs Letters, Dec. 1990, pp. 151-55, Vol. 256, No. 1,2.

#LEE et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, 1999, pp. 6292-6300, Vol.163.

#MUKHERJI et al., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, proceedings of the National Academy of Science, 1995, pp. 8078-82, Vol. 92.

#GILLIES et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, no. 1, pp. 47-54.

#JAIN, Sci. Am. 271:58-65, 1994.

#KAWAKAMI, et al., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with *in vivo* tumor rejection, Proc. Natl. Acad. Sci., 1994, Vol. 91, pp. 6458-6462.

#KWON et al., A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a cyntenic region on human chromosone 12, Proceedings of the National Academy of Sciences of USA, 88:20:9228-9232, October 15, 1991, Washington D.C., USA.

#LAZAR et al., Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, *Mol. Cell Biol.*, 1988, Vol. 8, pp. 1247-1252.

#MPSRCH Search Report Seg ID No. 22, p. 1-3 (2001).

#MPSRCH Search Report, for Seg ID No. 21, p. 1-2 (2001).

#OSBAND et al., Problems in the investigational study and clinical use of cancer immunotherapy, *Immunology Today*, 1990, 11(6):193-195.

#RIVOLTINI et al., Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes, *Journal of Immunology*, May 1996, pp. 3882-91.

#MARCHAND et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, *Int. J. Cancer*, 1995 63, 883-885, Wiley-Liss, Inc.

#ROSENBERG et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, *Nature Medicine*, March 1998, Vol 4, No. 3, pp. 321-327

#ROSENBERG, Cancer vaccines based on the identification of genes encoding cancer regression antigens, *Immunology Today*, Vol. 18, No. 4, April 1997, pp. 175-182.

#SALGALLER et al., Immunization against Epitopes in the Human Melanoma Antigen gp100 following Patient Immunization with Synthetic Peptides, *Cancer Research*, October 1996, pp. 4749-57, Vol. 56.

#SINKOVICS et al., Vaccination against human cancers (review), *International Journal of Cancer*, 2000, pp. 81-96, Vol. 16.

#SLINGLUFF et al., Melanomas with concordant loss of multiple differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, *Cancer Immunology & Immunotherapy*, 2000, pp. 661-72, Vol. 48, No. 12.

#SLINGLUFF et al., Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, *The Journal of Immunology*, April 1, 1993, pp. 2955-2963, vol. 150, No. 7, The American Association of Immunologists, USA.

#SPLITLER, LE, Cancer vaccines: the interferon analogy, Cancer Biotherapy, 1995, pp. 1-3, Vol. 10, No. 1.

#TAO et al., Studies of Aglycosylated Chimeric Mouse-Human IgG, J. Immunol., 1989, Vol. 143, No. 8, pp. 2595-2601.

#TIMMERMAN et al., Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, 1999, pp. 407-29, Vol. 50.

#VOGEL et al., Human 95kD melanocyte-specific secreted glycoprotein mRNA, 3' end EMBL Database, Accession No. M32295, November 26, 1990.

#YAMSHCHIKOV et al., Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations, Clinical Cancer Research, pp 909s-916s, Vol. 7, No. 3 supplement.

#ZAKS et al., Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, pp. 4902-08, Vol. 58.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:  
Serial No.: 09/214,836  
Filed: October 4, 1999  
For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2578-4230US  
Serial No.: 09/214,836  
Filing Date: 10/4/1999  
Title: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA

Attorney Docket No.: 2578-3938.1US  
Serial No.: 10/136,145  
Filing Date: 5/1/2002  
Title: MELANOMA ASSOCIATED ANTIGENIC POLYPEPTIDE, EPITOPES THEREOF AND VACCINES AGAINST MELANOMA

**Attorney Docket No.: 2578-4230.1US**

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Bretton L. Crockett

Registration No. 44,632

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: March 25, 2004

BLC/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

6

**Complete if Known**

Application Number	To be assigned
Filing Date	March 25, 2004
First Named Inventor	Figdor et al.
Group Art Unit	S. Rawlings, Ph.D. (presumed)
Examiner Name	1642 (presumed)
Attorney Docket Number	2578-4230.1US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		#US- 2002/0076392 A1	06-20-2002	Hoo	
		#US- 4,485,086	11/27/1984	Wong	
		#US- 5,376,531	12/27/1994	Anderson et al.	
		#US- 5,783,567	07-21-1998	Hedley et al.	
		#US- 5,844,075	12-01-1998	Kawakami et al.	
		#US- 5,874,560	02-23-1999	Kawakami et al.	
		#US- 5,891,432	04-06-1999	Hoo	
		#US- 5,965,381	10-12-1999	van der Bruggen et al.	
		#US- 5,965,535	10-12-1999	Chaux et al.	
		#US- 5,994,523	11-30-1999	Kawakami et al.	
		#US- 6,245,525 B1	06-12-2001	Martelange et al.	
		#US- 6,270,778 B1	08-07-2001	Kawakami et al.	
		#US- 6,291,430 B1	09-18-2001	Chaux et al.	
		#US- 6,303,756 B1	10-16-2001	Martelange et al.	
		#US- 6,369,211 B1	04-09-2002	Chaux et al.	
		#US- 6,407,063 B1	06-18-2002	Luiten et al.	
		#US- 6,426,217 B1	07-30-2002	Chaux et al.	
		#US- 6,500,919 B1	12/31/2002	Adema et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		#WO 00/20445	04-13-2000	Chaux		
		#WO 00/20581	04-13-2000	Ludwig Institute		
		#WO 95/29193	11-02-1995	The Government of the United States		
		#WO 98/31398	07-23-1998	Pangaea Pharmaceuticals, Inc.		
		#WO 99/06544	02-11-1999	The Immune Response Corp.		
		#WO 99/14326	03-25-1999	Ludwig Institute		
		#WO 99/45098	09-10-1999	van der Bruggen		
		#WO 99/53061	10-21-1999	Ludwig Institute		
		#EP 0 668 350 A	08-23-1995	Akzo Nobel N.V.		

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

6

**Complete if Known**

Application Number

To be assigned

Filing Date

March 25, 2004

First Named Inventor

Figdor et al.

Group Art Unit

S. Rawlings, Ph.D. (presumed)

Examiner Name

1642 (presumed)

Attorney Docket Number

2578-4230.1US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		#US-4,405,712	09-20-1983	Vande Woude et al.	
		#US-4,497,796	02-05-1985	Salser et al.	
		#US-4,727,028	02-23-1988	Santerre et al.	
		#US-4,740,463	04-26-1988	Weinberg et al.	
		#US-5,190,931	03-02-1993	Inouye	
		#US-5,208,149	05-04-1993	Inouye	
		#US-5,262,177	11-16-1993	Brown et al.	
		#US-5,342,774	08-30-1994	Boon et al.	
		#US-5,518,913	05-21-1996	Massie et al.	
		#US-5,837,511	11-17-1998	Falck-Pedersen et al.	
		#US-5,994,106	11-30-1999	Kovesdi et al.	
		#US-5,994,128	11-30-1999	Fallaux et al.	
		#US-6,033,908	03-07-2000	Bout et al.	
		#US-6,040,174	03-21-2000	Imler et al.	
		#US-6,537,560	03-25-2003	Kawakami et al.	
		#US-2003/0144482 A1	07-31-2003	Kawakami et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		#EP-0174608	03-19-1986	Leavitt		
		#WO 92/21767	12-10-1992	Bristol-Myers		
		#WO 93/14189	04-22-1993	Ludwig Institute		
		#WO 94/23067	10-13-1994	Abbott Labs		
		#WO 94/28152	12-08-1994	Transgene S.A.		
		#WO 95/02697	01-26-1995	Rhonepoulenc Rorer S.A.		
		#WO 95/22561	08-24-1995	Univ. of Virginia		
		#JP9027482A2	01-28-1997	Speedfam Co.		

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 6

**Complete if Known**

Application Number	To be assigned
Filing Date	March 25, 2004
First Named Inventor	Figdor et al.
Group Art Unit	S. Rawlings, Ph.D. (presumed)
Examiner Name	1642 (presumed)
Attorney Docket Number	2578-4230.1US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#ADEMA et al., Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA, The American Journal of Pathology, 1993, Vol. 143, No. 6, pp. 1579-1585.	
		#ADEMA, et al., Molecular Characterization of the Melanocyte Lineage-specific Antigen gp100, J. Biol. Chem., 1994, Vol. 269, No. 31, pp. 20126-20133	
		#ARCECI, RJ., The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, 1998, pp. 80-93, Vol. 76.	
		#BAKKER et al., Int J. Cancer, 1997 Jan 27, pp. 302-9, Vol. 70 (3).	
		#BODEY et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, 2000, pp. 2665-76, Vol. 20.	
		#BOON, T., Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, 1992, pp. 177-210, Vol. 58.	
		#BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Biol., 1990, 11:2129-2138.	
		#COX et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 1994, pp. 716-19, Vol. 264.	
		#CURTI, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.	
		#DE VRIES et al., Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and inhuman melanocytic lesions, Cancer Research, 1997, pp. 3223-3229, Vol. 57, No. 15.	
		#European Search Report, EP 94 20 0337, dated 27 July 1994.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

6

**Complete if Known**

Application Number

To be assigned

Filing Date

March 25, 2004

First Named Inventor

Figdor et al.

Group Art Unit

S. Rawlings, Ph.D. (presumed)

Examiner Name

1642 (presumed)

Attorney Docket Number

2578-4230.1US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#EZZELL, C., Cancer "vaccines": an idea whose time has come?, Journal of NIH Research, pp. 46-49, Vol. 7.	
		#GAO et al., Tumor vaccination that enhances antitumor T-cell responses does not inhibit th growth of established tumor, Journal of Immunotherapy, 2000, pp. 643-53, Vol. 23, No. 6.	
		#GURA, T., Systems for identifying drugs are often faulty, Science, 1997, pp. 1041-42, Vol. 278.	
		#HU et al., Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, 1996, pp. 2479-83, Vol. 56.	
		#JAEGER et al., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, 1996, pp. 162-69, Vol. 66, No. 2.	
		#KRISTENSEN et al., Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor, Febs Letters, Dec. 1990, pp. 151-55, Vol. 256, No. 1,2.	
		#LEE et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, 1999, pp. 6292-6300, Vol.163.	
		#MUKHERJI et al., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, proceedings of the National Academy of Science, 1995, pp. 8078-82, Vol. 92.	
		#GILLIES et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, no. 1, pp. 47-54.	
		#JAIN, Sci. Am. 271:58-65, 1994.	
		#KAWAKAMI, et al., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection, Proc. Natl. Acad. Sci., 1994, Vol. 91, pp. 6458-6462.	
		#KWON et al., A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a cyntenic region on human chromosome 12, Proceedings of the National Academy of Sciences of USA, 88:20:9228-9232, October 15, 1991, Washington D.C., USA.	
		#LAZAR et al., Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell Biol., 1988, Vol. 8, pp. 1247-1252.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

6

**Complete if Known**

Application Number

To be assigned

Filing Date

March 25, 2004

First Named Inventor

Figdor et al.

Group Art Unit

S. Rawlings, Ph.D. (presumed)

Examiner Name

1642 (presumed)

Attorney Docket Number

2578-4230.1US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#MPSRCH Search Report Seg ID No. 22, p. 1-3 (2001).	
		#MPSRCH Search Report, for Seg ID No. 21, p. 1-2 (2001).	
		#OSBAND et al., Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, 1990, 11(6):193-195.	
		#RIVOLTINI et al., Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes, Journal of Immunology, May 1996, pp. 3882-91.	
		#MARCHAND et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 1995 63, 883-885, Wiley-Liss, Inc.	
		#ROSENBERG et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nature Medicine, March 1998, Vol 4, No. 3, pp. 321-327	
		#ROSENBERG, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunology Today, Vol. 18, No. 4, April 1997, pp. 175-182.	
		#SALGALLER et al., Immunization against Epitopes in the Human Melanoma Antigen gp100 following Patient Immunization with Synthetic Peptides, Cancer Research, October 1996, pp. 4749-57, Vol. 56.	
		#SINKOVICS et al., Vaccination against human cancers (review), International Journal of Cancer, 2000, pp. 81-96, Vol. 16.	
		#SLINGLUFF et al., Melanomas with concordant loss of multiple differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, Cancer Immunology & Immunotherapy, 2000, pp. 661-72, Vol. 48, No. 12.	
		#SLINGLUFF et al., Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, The Journal of Immunology, April 1, 1993, pp. 2955-2963, vol. 150, No. 7, The American Association of Immunologists, USA.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**Complete if Known**

Application Number

To be assigned

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	6	of	6	Application Number	To be assigned
				Filing Date	March 25, 2004
				First Named Inventor	Figdor et al.
				Group Art Unit	S. Rawlings, Ph.D. (presumed)
				Examiner Name	1642 (presumed)
				Attorney Docket Number	2578-4230.1US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#SPLITLER, LE, Cancer vaccines: the interferon analogy, Cancer Biotherapy, 1995, pp. 1-3, Vol. 10, No. 1.	
		#TAO et al., Studies of Aglycosylated Chimeric Mouse-Human IgG, J. Immunol., 1989, Vol. 143, No. 8, pp. 2595-2601.	
		#TIMMERMAN et al., Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, 1999, pp. 407-29, Vol. 50.	
		#VOGEL et al., Human 95kD melanocyte-specific secreted glycoprotein mRNA, 3' end EMBL Database, Accession No. M32295, November 26, 1990.	
		#YAMSHCHIKOV et al., Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations, Clinical Cancer Research, pp 909s-916s, Vol. 7, No. 3 supplement.	
		#ZAKS et al., Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, pp. 4902-08, Vol. 58.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:  
 Serial No.: 09/214,836  
 Filed: October 4, 1999  
 For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

